Xeris Pharmaceuticals (XERS) AI Stock Analysis

• Market Cap: $819.99M
• Dividend Yield: N/A
• Average Volume (3M): 1.98M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: 29.88%
• EPS Growth: 35.11%
• Country: US
• Employees: 394
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 160,155,000
• 10 Day Avg. Volume: 2,119,993
• 30 Day Avg. Volume: 1,982,940
• PEG Ratio: -0.84
• Price to Book (P/B): -22.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -30.48
• Enterprise Value/Market Cap: 1.29
• Enterprise Value/Revenue: 1.33
• Enterprise Value/Gross Profit: 5.87
• Enterprise Value/Ebitda: -16.80
• 1Y Price Target: $6.00
• Price Target Upside: 17.19% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 65 Neutral
• Price Target: $5.50 ▲(7.42%Upside)

Xeris Pharmaceuticals' overall score is driven by strong earnings call results and bullish technical indicators. The company's financial performance shows robust revenue growth but is tempered by profitability and leverage challenges. Positive corporate events also bolster the score, though the valuation remains a concern due to the negative P/E ratio.

Positive Factors

Earnings Performance

Xeris delivered strong revenues, representing around 48% year-over-year growth, marking another consecutive quarter of over 20% year-over-year growth.

Market Confidence

Analyst reiterates an Outperform rating, reflecting a strong belief in the company's future prospects.

Revenue Growth

Record growth of Recorlev with revenue growing approximately 141% year-over-year, driven by a 124% increase in average patients on therapy.

Negative Factors

Investor Expectations

Some investors might still want more granular details on the roadmap for Recorlev becoming a blockbuster product, which could take some time.

Product Uncertainty

Plans to drive broader adoption in endogenous Cushing’s syndrome via sales force expansion and stepwise investments in Recorlev's commercial infrastructure over time were highlighted, yet there remains uncertainty in execution.

Xeris Pharmaceuticals Business Overview & Revenue Model

Company Description

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

How the Company Makes Money

Xeris Pharmaceuticals generates revenue primarily through the sale of its pharmaceutical products, including Gvoke. The company's revenue model is based on the commercialization and distribution of its proprietary drug formulations. Xeris leverages partnerships with healthcare providers, distributors, and pharmacies to expand its market reach and increase product adoption. Additionally, Xeris may engage in licensing agreements or collaborations with other pharmaceutical companies to further monetize its technology platform and product pipeline. The company's earnings are influenced by factors such as market demand for its products, pricing strategies, and the effectiveness of its sales and marketing efforts.

Xeris Pharmaceuticals Financial Statement Overview

Summary

Xeris Pharmaceuticals shows strong revenue growth, but faces challenges with profitability and leverage. Despite improving operational efficiency, negative equity and cash flow issues remain concerns.

Income Statement

Xeris Pharmaceuticals has shown significant revenue growth, with Total Revenue increasing from $49.59M in 2020 to $222.55M in TTM (Trailing-Twelve-Months). Gross Profit Margin remains strong, but the company is facing challenges with profitability, as evidenced by negative Net Profit Margin and EBIT Margin. The company is improving its EBITDA Margin, indicating better operational efficiency.

Balance Sheet

The company's balance sheet reveals high leverage with a negative Stockholders' Equity and a substantial Debt-to-Equity Ratio, indicating financial risk. Despite growing assets, the negative equity and increasing total liabilities highlight potential solvency concerns. The Equity Ratio reflects this weak equity position.

Cash Flow

Xeris Pharmaceuticals has improved its Free Cash Flow year-over-year, but it remains negative, indicating cash constraints. The Operating Cash Flow to Net Income Ratio suggests operational cash flow struggles. The company must focus on enhancing cash flow generation to support growth and reduce reliance on external financing.

Breakdown	Dec 2024	Dec 2023	Dec 2023	Dec 2023	Dec 2023
Income Statement
Total Revenue	203.07M	163.91M	163.91M	163.91M	163.91M
Gross Profit	166.24M	135.27M	135.27M	135.27M	135.27M
EBITDA	-11.30M	-23.73M	-23.73M	-23.73M	-23.73M
Net Income	-54.84M	-62.26M	-62.26M	-62.26M	-62.26M
Balance Sheet
Total Assets	323.06M	322.60M	322.60M	322.60M	322.60M
Cash, Cash Equivalents and Short-Term Investments	71.62M	72.45M	72.45M	72.45M	72.45M
Total Debt	271.45M	229.19M	229.19M	229.19M	229.19M
Total Liabilities	352.68M	329.38M	329.38M	329.38M	329.38M
Stockholders Equity	-29.61M	-6.78M	-6.78M	-6.78M	-6.78M
Cash Flow
Free Cash Flow	-37.85M	-49.29M	-49.29M	-49.29M	-49.29M
Operating Cash Flow	-36.98M	-47.02M	-47.02M	-47.02M	-47.02M
Investing Cash Flow	4.88M	-6.00M	-6.00M	-6.00M	-6.00M
Financing Cash Flow	36.17M	-1.61M	-1.61M	-1.61M	-1.61M

Xeris Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.12
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XERS, the sentiment is Positive. The current price of 5.12 is above the 20-day moving average (MA) of 4.97, above the 50-day MA of 4.82, and above the 200-day MA of 4.03, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 56.24 is Neutral, neither overbought nor oversold. The STOCH value of 42.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XERS.

Xeris Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XERS	65 Neutral	$819.99M	―	222.83%	―	29.88%	35.11%
ZYME	59 Neutral	$1.01B	―	-29.80%	―	85.05%	15.96%
ABCL	59 Neutral	$1.47B	―	-15.59%	―	-35.41%	-12.26%
XNCR	55 Neutral	$638.40M	―	-33.48%	―	-25.88%	-29.16%
PRAX	55 Neutral	$1.10B	―	-63.56%	―	270.02%	32.69%
NRIX	53 Neutral	$860.06M	―	-50.67%	―	41.86%	10.48%
Sector *	52 Neutral	$7.46B	-0.04	-63.82%	2.49%	16.43%	<0.01%

Xeris Pharmaceuticals Corporate Events

Xeris Pharmaceuticals Holds 2025 Annual Stockholders Meeting

On June 4, 2025, Xeris Biopharma Holdings, Inc. held its 2025 Annual Meeting of Stockholders, where key decisions were made. Three individuals were elected as Class I directors to serve until the 2028 Annual Meeting. Additionally, Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025. The stockholders also approved the compensation of the Company’s Named Executive Officers on a non-binding advisory basis.

The most recent analyst rating on (XERS) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Xeris Pharmaceuticals stock, see the XERS Stock Forecast page.

Xeris Pharmaceuticals Hosts Analyst and Investor Day

Xeris Pharmaceuticals announced its first Analyst and Investor Day scheduled for June 3, 2025, in New York City, where senior management will discuss the company’s growth strategy and financial outlook. The event aims to highlight the potential of products like Recorlev® and XP-8121, emphasizing their expected impact on revenue growth and the treatment landscape for conditions such as hypothyroidism, potentially affecting stakeholders by demonstrating the company’s commitment to long-term value creation.

The most recent analyst rating on (XERS) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Xeris Pharmaceuticals stock, see the XERS Stock Forecast page.